Canntab Therapeutics Limited Stock Buy Hold or Sell Recommendation
| CTABF Stock | USD 0.0001 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Canntab Therapeutics Limited is 'Strong Sell'. Macroaxis provides Canntab Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CTABF positions.
Check out Canntab Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Canntab and provide practical buy, sell, or hold advice based on investors' constraints. Canntab Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Canntab |
Execute Canntab Therapeutics Buy or Sell Advice
The Canntab recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Canntab Therapeutics Limited. Macroaxis does not own or have any residual interests in Canntab Therapeutics Limited or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Canntab Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Canntab Therapeutics Trading Alerts and Improvement Suggestions
| Canntab Therapeutics generated a negative expected return over the last 90 days | |
| Canntab Therapeutics has high historical volatility and very poor performance | |
| Canntab Therapeutics has some characteristics of a very speculative penny stock | |
| Canntab Therapeutics Limited has accumulated 126.2 K in total debt with debt to equity ratio (D/E) of 2.43, implying the company greatly relies on financing operations through barrowing. Canntab Therapeutics has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Canntab Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Canntab Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Canntab Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Canntab to invest in growth at high rates of return. When we think about Canntab Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K). | |
| Canntab Therapeutics Limited has accumulated about 691.11 K in cash with (2.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Canntab Therapeutics shares are held by company insiders |
Canntab Therapeutics Returns Distribution Density
The distribution of Canntab Therapeutics' historical returns is an attempt to chart the uncertainty of Canntab Therapeutics' future price movements. The chart of the probability distribution of Canntab Therapeutics daily returns describes the distribution of returns around its average expected value. We use Canntab Therapeutics Limited price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Canntab Therapeutics returns is essential to provide solid investment advice for Canntab Therapeutics.
| Mean Return | -1.44 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 11.69 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Canntab Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Canntab Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Canntab Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Canntab Therapeutics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Canntab pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.13 | |
β | Beta against Dow Jones | -2.66 | |
σ | Overall volatility | 11.88 | |
Ir | Information ratio | -0.13 |
Canntab Therapeutics Volatility Alert
Canntab Therapeutics Limited is displaying above-average volatility over the selected time horizon. Canntab Therapeutics Limited appears to be a penny stock. Although Canntab Therapeutics Limited may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Canntab Therapeutics Limited or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Canntab instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Canntab Therapeutics Fundamentals Vs Peers
Comparing Canntab Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Canntab Therapeutics' direct or indirect competition across all of the common fundamentals between Canntab Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Canntab Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Canntab Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Canntab Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Canntab Therapeutics to competition |
| Fundamentals | Canntab Therapeutics | Peer Average |
| Return On Equity | -6.02 | -0.31 |
| Return On Asset | -0.82 | -0.14 |
| Operating Margin | (26.95) % | (5.51) % |
| Current Valuation | 1.73 M | 16.62 B |
| Shares Outstanding | 38.91 M | 571.82 M |
| Shares Owned By Insiders | 15.08 % | 10.09 % |
| Price To Book | 4.74 X | 9.51 X |
| Price To Sales | 1.83 X | 11.42 X |
| Revenue | 293.36 K | 9.43 B |
| Gross Profit | (939.01 K) | 27.38 B |
| EBITDA | (2.49 M) | 3.9 B |
| Net Income | (3.69 M) | 570.98 M |
| Cash And Equivalents | 691.11 K | 2.7 B |
| Cash Per Share | 0.02 X | 5.01 X |
| Total Debt | 126.2 K | 5.32 B |
| Debt To Equity | 2.43 % | 48.70 % |
| Current Ratio | 0.57 X | 2.16 X |
| Book Value Per Share | (0.04) X | 1.93 K |
| Cash Flow From Operations | (2.85 M) | 971.22 M |
| Earnings Per Share | (0.1) X | 3.12 X |
| Number Of Employees | 7 | 18.84 K |
| Beta | 0.9 | -0.15 |
| Market Capitalization | 774.29 K | 19.03 B |
| Total Asset | 2.85 M | 29.47 B |
| Z Score | 3.6 | 8.72 |
| Net Asset | 2.85 M |
Canntab Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Canntab . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About Canntab Therapeutics Buy or Sell Advice
When is the right time to buy or sell Canntab Therapeutics Limited? Buying financial instruments such as Canntab Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Canntab Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Canntab Pink Sheet
Canntab Therapeutics financial ratios help investors to determine whether Canntab Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canntab with respect to the benefits of owning Canntab Therapeutics security.